| Literature DB >> 26317779 |
Abdul Rouf Mir1, Moin Uddin1, Farzana Khan1, Khursheed Alam1, Asif Ali1.
Abstract
Increased oxidative stress under hyperglycemic conditions, through the interaction of AGEs with RAGE receptors and via activation of interleukin mediated transcription signalling, has been reported in cancer. Proteins modifications are being explored for their roles in the development and progression of cancer and autoantibody response against them is gaining interest as a probe for early detection of the disease. This study has analysed the changes in histone H1 upon modification by methylglyoxal (MG) and its implications in auto-immunopathogenesis of cancer. Modified histone showed modifications in the aromatic residues, changed tyrosine microenvironment, intermolecular cross linking and generation of AGEs. It showed masking of hydrophobic patches and a hypsochromic shift in the in ANS specific fluorescence. MG aggressively oxidized histone H1 leading to the accumulation of reactive carbonyls. Far UV CD measurements showed di-carbonyl induced enhancement of the alpha structure and the induction of beta sheet conformation; and thermal denaturation (Tm) studies confirmed the thermal stability of the modified histone. FTIR analysis showed amide I band shift, generation of a carboxyethyl group and N-Cα vibrations in the modified histone. LCMS analysis confirmed the formation of Nε-(carboxyethyl)lysine and electron microscopic studies revealed the amorphous aggregate formation. The modified histone showed altered cooperative binding with DNA. Modified H1 induced high titre antibodies in rabbits and the IgG isolated form sera of rabbits immunized with modified H1 exhibited specific binding with its immunogen in Western Blot analysis. IgG isolated from the sera of patients with lung cancer, prostate cancer, breast cancer and cancer of head and neck region showed better recognition for neo-epitopes on the modified histone, reflecting the presence of circulating autoantibodies in cancer. Since reports suggest a link between AGE-RAGE axis and carcinogenesis, glycoxidation of histone H1 and its immunogenicity paves ways for understanding role of glycoxidatively damaged nuclear proteins in cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26317779 PMCID: PMC4552624 DOI: 10.1371/journal.pone.0136197
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1UV profile of native histone H1 (-□-), and histone H1 modified with 2.5 mM (-▲-), 5 mM (-●-), 7.5 mM (-■-) and 10 mM (-_-), methylglyoxal.
Fig 2Fluorescence profile of native histone H1(-□-), and histone H1 modified with 2.5 mM (-▲-), 5 mM (-●-), 7.5 mM (-■)-) and 10 mM (-*-), methylglyoxal.
Fig 3PAGE:
PAGE analysis of native and MG modified histone H1: 25 μg each of native histone H1 and 2.5, 5, 7.5 and 10 mM methylglyoxal modified counterparts were loaded into the wells of 10% polyacrylamide gel under non denaturing conditions (lane 1–5), lane 6 shows the molecular weight marker.
Fig 4AGE fluorescence profile of native histone H1(thin line), and histone H1 modified with 7.5 mM methylglyoxal (thick line).
Fig 5ANSfluorescence profile of native histone H1(thick line), and histone H1 modified with 7.5 mM methylglyoxal (thin line).
Fig 6Protein-bound carbonyl concentration in native (H1) and MG modified histone (MG-H1).
Fig 7CD spectra of native histone H1 (dotted line), and histone H1 modified with 7.5 mM methylglyoxal (thick line) in far UV region (200–250 nm).
Fig 8Temperature-induced thermal unfolding profile showing changes in ellipticity at 222 nm for native histone H1 (dotted line) and MG modified histone H1 (thick line).
Fig 9FTIR-ATR spectroscopic analysis of native (A) and MG modified histone H1 (B) recorded between 1000 cm-1 and 3500 cm-1.
Fig 10LCMS spectra of standard CEL(a) native histone H1(b) and MG modified histone H1(c).
Fig 11SEM micrograph of MG modified histone H1 (a) of native histone H1 (b) with image scale bar of 5 μm viewed at 5000×.
Fig 12CD spectra of native histone H1 with DNA (-----), MG modified H1 with DNA (-∆-∆-) and native DNA (─) in far UV region (220–300 nm).
Fig 13Immunoblot showing binding of anti-MG-H1antibodies induced in rabbits with native and MG-H1.
A1 and A2 representSDS PAGE of native and MG-H1 respectively. B1 and B2 are the immunoblots depicting binding of anti-MG-H1 antibodies to native H1 and MG-H1 respectively.
Fig 14Binding of serum autoantibodies in cancer patients to native H1 and MG modified histone H1.
(A) Binding of serum autoantibodies in lung cancer patients (sera no. 1–27) to native (□) and MG modified histone H1 (■). Normal human sera (NHS) served as negative control. The histogram shows mean absorbance values.(B) Binding of serum autoantibodies in prostate cancer patients (sera no. 28–46) to native (□) and MG modified histone H1 (■). Normal human sera (NHS) served as negative control. The histogram shows mean absorbance values.(C) Binding of serum autoantibodies in breast cancer patients (sera no. 47–68) to native (□) and MG modified histone H1 (■). Normal human sera (NHS) served as negative control. The histogram shows mean absorbance values.(D) Binding of serum autoantibodies in head and neck cancer patient (sera no. 69–83) to native (□) and MG modified histone H1 (■). Normal human sera (NHS) served as negative control. The histogram shows mean absorbance values.
Competitive inhibition of IgG isolated from sera of cancer patients with native and MG modified H1.
| Type of Cancer | Sample Numbers | Max. percent inhibition | Mean±SD | ||
|---|---|---|---|---|---|
| Native H1 | MG-H1 | Native H1 | MG-H1 | ||
|
| 1,2,4,5,7,8,10,12,13,14,15,16,17,18,19,22,23,26,27 | 24.3,23.5,31.1,32.3,28.8,27.2,34.3,27.8,36.2,24.2,26.3,27.1,27.3,20.8,23.9,26.9,28.3,31.5,26.9 | 73.2,69.5,69.7,76.5,71.8,65.9,68.3,68.6,76.1,63.8,71.1,67.5,70.2,65.4,66.3,59.7, 61.5,72.4,61.8 | 27.82±8.38 | 68.3±8.6 |
|
| 28,30,31,33,34,35,36,38,39,41,43,45 | 28.5,37.1, 22.5,22.5, 34.9,27.8, 35.1,28.9, 31.2,24.3, 32.6,28.5 | 68.161.4, 68.9,55.2, 68.7,52.2, 62.7,66.3, 69.7,63.7, 62.9,69.4 | 29.49±7.61 | 64.1±5.6 |
|
| 48,49,50,52,53,54,56,57,59,60,61,63,64,66,67 | 24.1,28.6,28.8,27.3,29.5,27.2,21.4,29.5,32.4,24.6,24.8,29.8,26.8,26.2,27.4 | 61.3,64.5,66.4,71.5,65.3,65.4,68.1,65.4,71.2,61.2,68.1,64.2,65.863.7,65.3 | 27.2±5.8 | 65.8±5.7 |
|
| 69,71,72,73,76,77,78,82 | 28.9,27.1,26.4,26.7,21.3,26.1,20.2,19.4, | 57.1,52.3,52.8,55.3,52.5,49.2,51.6,50.9 | 24.51±9.5 | 52.7±7.6 |
Fig 15Band shift assayof IgG isolated from sera of cancer patient binding to native H1 and MG-H1.
Electrophoresis was performed on 10% SDS–PAGE for 3-4 hr at 80 V. (A)25 μg of MG-H1 (lane 1) was incubated with 30, 40, 50 and 60 μg of anti-MG-H1 IgG (Lane 3–6). Lane 2 shows IgG alone. (B) 25 μg of native H1 (lane 1) was incubated with 30, 40, 50 and 60 μg of anti-MG-H1 IgG (Lane 3–6). Lane 2 shows IgG alone.